Bexxar highly effective as first-line treatment for patients with non-Hodgkin's lymphoma
Study shows radioactive antibodies produce durable remissions of three years or more NEW ORLEANS - A radioacti... long as three years with the treatment. Molecular remissions were determined by a rigorous use of polymerase chain reaction, or PCR, technology, arguably the mos...Double-drug therapy may benefit some multiple sclerosis patients
...age, there are periods of intermittent attacks and remissions before the disease begins a course of steady progression. Other less common forms include primary-progressive MS, in which the symptoms generally do not remit, and progressive-relapsing MS, which is characterized by obvious acute attacks....Study shows infliximab can maintain long-term remissions in Crohns disease
...ith the monoclonal antibody infliximab can prolong remissions in patients with moderate to severe Crohn's disease , a multi-center research team reports today at the Digestive Disease Week meeting in Atlanta. The ACCENT-I clinical trial is the first large-scale trial of infliximab (also known as REMICADE...Study shows infliximab can prolong remissions in Crohns disease
...ith the monoclonal antibody infliximab can prolong remissions in patients with moderate to severe Crohn's diseas...sting remissions. For patients receiving placebo, remissions lasted a median of 19 weeks. For those receiving 5mg/kg of infliximab, they lasted twice as long, a...Gleevec shows promise in treating another form of leukemia
...response after a single three-week course, and the remissions have, so far, lasted up to 29 months after treatment. To date, the two-year disease-free survival is 85 percent says the study's lead author, Deborah Thomas, M.D., assistant professor in the Department of Leukemia. "This is a promising treatment tha...Clinical trial of Etanercept for Wegener's disease shows no benefit
...uate the ability of etanercept to maintain disease remissions in a serious autoimmune disorder has failed to sho...of patients in the two groups who achieved disease remissions of at least six months duration: 69.7 percent among the etanercept-treated patients, compared with 7...Study finds new designer drug is potent treatment for chronic myelogenous leukemia
...ith a human form of CML, AMN107 produced lengthier remissions than Gleevec and triggered remissions in animals in which the disease had become resistant to Gleevec. Side effects in the animals were mi...Study finds new designer drug is potent treatment for chronic myelogenous leukemia
...ith a human form of CML, AMN107 produced lengthier remissions than Gleevec and triggered remissions in animals in which the disease had become resistant to Gleevec. Side effects in the animals were mi...